Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

15.40USD
5:28pm BST
Change (% chg)

$-0.83 (-5.14%)
Prev Close
$16.24
Open
$16.73
Day's High
$16.91
Day's Low
$15.11
Volume
9,025
Avg. Vol
8,447
52-wk High
$51.90
52-wk Low
$12.75

Chart for

About

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was... (more)

Overall

Beta: -0.31
Market Cap(Mil.): $72.86
Shares Outstanding(Mil.): 2.03
Dividend: --
Yield (%): --

Financials

  OPNT.OQ Industry Sector
P/E (TTM): 14.34 30.93 32.76
EPS (TTM): 2.51 -- --
ROI: 231.11 15.07 14.61
ROE: 2,031.09 16.60 16.34

BRIEF-Opiant Pharma Reports Financial Results

* OPIANT PHARMACEUTICALS, INC. REPORTS FINANCIAL RESULTS FOR AUGUST 1, 2017, THROUGH DECEMBER 31, 2017, AND PROVIDES CORPORATE UPDATE Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Opiant Pharma Says Teva Filed ANDA With FDA For Marketing Approval Of Generic Version Of Narcan 2 Mg/Spray

* OPIANT PHARMACEUTICALS SAYS ON FEB 27, CO AND ADAPT PHARMA OPERATIONS LIMITED RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA INC - SEC FILING

05 Mar 2018

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003

12 Feb 2018

BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty

* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

08 Feb 2018

Earnings vs. Estimates